title: Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
abstract: OBJECTIVE
  The most recent and powerful prognostic instrument established for myelodysplastic syndromes (MDS) is the International Prognostic Scoring System (IPSS), which is primarily based on medullary blast cell count, number of cytopenias, and cytogenetics. Although this prognostic system has substantial predictive power in MDS, further refinement is necessary, especially as far as lower-risk patients are concerned. Histologic parameters, which have long proved to be associated with outcome, are promising candidates to improve the prognostic accuracy of the IPSS. Therefore, we assessed the additional predictive power of the presence of abnormally localized immature precursors (ALIPs) and CD34 immunoreactivity in bone marrow (BM) biopsies of MDS patients.
  
  
  METHODS
  Cytogenetic, morphologic, and clinical data of 184 MDS patients, all from a single institution, were collected, with special emphasis on the determinants of the IPSS score. BM biopsies of 173 patients were analyzed for the presence of ALIP, and CD34 immunoreactivity was assessable in 119 patients. Forty-nine patients received intensive therapy.
  
  
  RESULTS
  The presence of ALIP and CD34 immunoreactivity significantly improved the prognostic value of the IPSS, with respect to overall as well as leukemia-free survival, in particular within the lower-risk categories. In contrast to the IPSS, both histologic parameters also were predictive of outcome within the group of intensively treated MDS patients.
  
  
  CONCLUSIONS
  Our data confirm the importance of histopathologic evaluation in MDS and indicate that determining the presence of ALIP and an increase in CD34 immunostaining in addition to the IPSS score could lead to an improved prognostic subcategorization of MDS patients.
authors.affiliation: Department of Hematology, University Hospitals, University of Leuven, Leuven, Belgium. estelle.verburgh@uz.kuleuven.ac.be
authors.forename: E
authors.initials: E
authors.lastname: Verburgh
authors.forename: R
authors.initials: R
authors.lastname: Achten
authors.forename: B
authors.initials: B
authors.lastname: Maes
authors.forename: A
authors.initials: A
authors.lastname: Hagemeijer
authors.forename: M
authors.initials: M
authors.lastname: Boogaerts
authors.forename: C
authors.initials: C
authors.lastname: De Wolf-Peeters
authors.forename: G
authors.initials: G
authors.lastname: Verhoef
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000378:metabolism; D001853:Bone Marrow / Q000378:metabolism / Q000473:pathology*; D002648:Child; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000175:diagnosis* / Q000378:metabolism; D009367:Neoplasm Staging; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D018952:Antigens, CD34